Enterprise Value to EBITDA Ratio: Enochian BioSciences (RENB)
The price trajectory of Renovaro Inc. (RENB) reflects an EV/EBITDA multiple of . Renovaro Inc. is developing AI technologies and cellular analysis to combat tumors and viruses, thereby reducing reliance on a single business line. However, a high burn rate and uncertainty regarding regulatory verdicts create significant investment risks. Meanwhile, an established reagent storage system eliminates any disruptions in the conduct of current research.
Comprehensive metric breakdowns and analytics for renovarobio.com (RENB)
- current price and projected stock value:
- company stock exchange capitalization indicators:
- business book valuation details:
- issuer credit burden and liquidity indicators:
- business earnings and investment ratios data:
RENB - Company Net Income|Projected Future Earnings Renovaro Inc.|RENB - P/E Multiple|Future Price to Earnings Renovaro|RENB - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization RENB|RENB - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months Renovaro|RENB - Earnings per share for the trailing year|Quarterly EPS earnings growth renovarobio.com|RENB - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Renovaro Inc.
- company sales and revenue statistics:
Initial company analysis:RENB (Enochian BioSciences)
This ratio determines the business value inclusive of net debt relative to operating profit, allowing investors to identify undervalued assets beyond market noise. By analyzing fluctuations in the EV/EBITDA level of Renovaro Inc. (RENB), one can assess the efficiency of the capital structure, where the optimization of chemical compound logistics for oncology research should convert into operating income growth and a reduction of the final multiple.
Competitor analysis for Renovaro Inc.
EV/EBITDA Multiple ONC (BeiGene Corp)|HALO - Enterprise Value to EBITDA Ratio|RVMD: Enterprise Value to EBITDA Ratio|AAPG - EV/EBITDA Multiple|CG Oncology (CGON) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|UroGen Pharma Ltd - Business Value to Operating Income Before Depreciation|BCAX (Bicara Bio) - EV/EBITDA Multiple|Company Value to EBITDA Personalis Genomics PSNL|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Erasca, Inc. (ERAS)|DCTH (delcath.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple YMAB (Y-mAbs Therapeutics, Inc.)|Aura Biosciences Inc (AURA) - Company Value to EBITDA|CADL - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ARAY (Accuray, Inc.) - Enterprise Value to Operating Income Before Depreciation|sellaslifesciences.com (SLS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA actuatetherapeutics.com (ACTU)|Enterprise Value to EBITDA Ratio CTOR|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization HURA|EV/EBITDA Multiple TARA|EV/EBITDA Multiple Fate Pharma (FATE)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Aadi Bioscience WHWK|Business Value to Operating Income Before Depreciation TCRX|CSBR - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA XBiotech Inc.|CVM (cel-sci.com) - Enterprise Value to EBITDA Ratio|OS Therapies, Inc. - Business Value to Operating Income Before Depreciation|RADX (Radiopharm Theranostics) - EV/EBITDA Multiple|Artiva (ARTV) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Adlai Nortye Ltd. (ANL)|Veru Inc - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple TPST (Tempest Tx)|XLO - Enterprise Value to EBITDA Ratio|MURA: Enterprise Value to EBITDA Ratio|Total Company Value to Operating Income Before Depreciation Ratio Kairos Pharma Ltd KAPA|onkuretherapeutics.com (OKUR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CytoMed Therapeutics Limited - Business Value to Operating Income Before Depreciation|CRIS (Curis Inc.) - EV/EBITDA Multiple|Company Value to EBITDA Apollomics Corp APLM|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tharimmune, Inc. (THAR)|advanbiomed.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple GNPX (Genprex)|Calidi Biotherapeutics Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Sunshine Biopharma - EV/EBITDA Multiple|Xenetic Biosciences (XBIO) - Enterprise Value to EBITDA Ratio|SLRX: EV/EBITDA Multiple|purple-biotech.com (PPBT) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization American Oncology Network Inc|Enterprise Value to Operating Income Before Depreciation BGNE (BeiGene Ltd.)|EV/EBITDA Multiple CKPT|Enterprise Value to EBITDA Ratio Elevation Oncology Inc. ELEV|EV/EBITDA Multiple ICAD (iCAD)|Ikena Oncology Inc. (IKNA) - Company Value to EBITDA|NTBL - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation VIRX (Viracta Therapeutics)|MOR (MorphoSys Corp) - Enterprise Value to EBITDA Ratio|NAYA Biosciences Corp - Business Value to Operating Income Before Depreciation|AAPGV (Ascentage Pharma Group) - EV/EBITDA Multiple
